Pravastatin for coronary secondary prevention in patients with myocardial infarction or instable angina pectoris: A pharmacoeconomic evaluation;Pharmakoökonomische bewertung von pravastatin in der koronaren sekundärprävention bei patienten mit myokardinfarkt oder instabiler angina pectoris eine: Analyse auf der grundlage der LIPID-studie

Praxis

Volumn 89, Issue 18, 2000, Pages 745-752

  Szucs, T D ^a   Bertel, O ^a   Darioli, R ^a   Gutzwiller, F ^a   Mordasini, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Coronary heart disease; Cost; HMG CoA reductase inhibitors; Instable angina pectoris; Lipids; Myocardial infarction; Pravastatin; Rentability

Indexed keywords

PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ANGINA PECTORIS; ARTICLE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; SWITZERLAND; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MORTALITY; RECURRENT DISEASE; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; PRAVASTATIN; RECURRENCE;

EID: 0034720311     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bundesamt für Statistik, Hrsg.: Statistisches Jahrbuch der Schweiz. Zürich: Verlag Neue Zürcher Zeitung, 1995.
2. Gesetz zur Krankenversicherung (KVG), 1.1.1995, Bern, Eidg. Druckmittel-Zentrale.
3. Pitt B, Furberg CD, for the PLAC I and PLAC II investigtors: Reduction in cardiovascular events during treatment with pravastatin: pooled analysis from coronary and carotid atherosclerosis intervention trials. Eur Heart J 1994; 15: 2565.
4. Pitt B, Ellis SG, Mancini GBJ, Rosman HS, McGovern ME: Design and recruitment in the United States of a multiplecenter quantitative angiographic trial of pravastatin to limit atherosclerosis in coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31-35. (Pubitemid 23184358)
5. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ: Reduction in cardiovascular events during pravastatin therapy. Circulation 1995; 92: 2419-2425.
6. Scandinavian Simvastatin Survival Study Group (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383-1389.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group (WOS): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995), 1301-1307.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E for the cholesterol and recurrent events trial investigators (CARE): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009. (Pubitemid 26338729)
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
10. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L: Cost effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409-414. (Pubitemid 26277019)
11. Berger K, Klose G, Szucs TD: Die Wirtschaftlichkeit von Arzneimiteltherapien. Eine sozioökonomische Analyse der HMG-CoA-Reduktase-Hemmung bei KHK-Patienten am Beispiel von Pravastatin. Med Klin 1997; 92; 363-369.
12. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Cost-effectiveness of cholesterol lowering. Eur Heart J 1996; 17: 1001-1007.
13. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336. (Pubitemid 27057183)
14. Pedersen TR, Kjekshus J, Berg K, Olsson AD, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergoman O, Thorgeirsson G, Jönsson B, Schwartz JS: Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1-7.
15. Szucs TD, Guggenberger G, Berger K, März W, Schäfer J. Pharmakoökonomische Bewertung von Pravastatin in der koronaren Sekundärprävention bei Patienten. Eine Analyse auf der Grundlage der CARE-Studie. Herz 1998; 23: 319-29 (5).
16. Schweizerischer Diagnoseindex, Interkontinental Medical Statistics (IMS), Zug, September 1997.
17. Spitalstatistik, H+ (vormals VESKA), Aarau, 1997.
18. Szucs TD, Lüscher TF, Gutzwiller F: Einfluss der medikamentösen Cholesterinsenkung auf den Ressourcenverbrauch im Gesundheitswesen - Bedeutung der Scandinavian Simvastatin Survival Study (4-S Studie) für die Kostenreduktion unter Schweizer Verhältnissen. Schw Med Wschr 1997; 127: 1819-1823. (Pubitemid 27470815)
19. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations on reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-1341. (Pubitemid 26346934)
20. Beck JR, Kassirer JP, Pauker SG et al.: A convenient approximation of life expectancy - the DEALE. I. Validation of the method. Am J Med 1982, 73, 883-888. (Pubitemid 13211834)
21. Beck JR, Kassirer JP, Pauker SG et al.: A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-making. Am J Med 1982, 73, 889-897. (Pubitemid 13211835)
22. Tengs TO, Adams ME, Pliskin JS: Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390.
23. Laupacis A, Feeny CD, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J 1992; 146 (4): 473-481.
24. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6.
25. WOSCOPS Investigators. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998; 97: 1440-5.
26. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettit D, McMurray J, Shepherd J for the West of Scotland Coronary Prevention Group: The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.
27. Naegeli B, Bertel O, Urban P, Angehrn W, Sigrist P, Staufer J-Ch, Baumann PC, Jolliet PH, Simeon-Dubach D, Meier B, Wunderlin R: Der akute Myokardinfarkt in der Schweiz: Resultate aus dem PIMICS-Herzinfarkt Register. Schweiz med Wschr 1998; 128: 729-736. (Pubitemid 28218819)
28. Szucs T, Berger K, Schulte-Hillen, Kleber FX: Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klin 1996; 91: 112-118. (Pubitemid 26076926)
29. Goldmann L, Sia STB, Cook EF, Rutherford JD, Weinstein MC: Costs and effectiveness of routine therapy with long-term beta-adreneric antagonists after acute myocardial infarction. N Engl J Med 1988; 319: 152-157.
30. Taylor WC, Pass TM, Shephard DS, Komaroff AL: Cost-effectiveness of cholesterol reduction for the primary prevention of coronary heart disease in men. Preventing disease: Beyond the rhetoric. New York: Springer 1990.
31. Stason WB, Weinstein MC: Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-739. (Pubitemid 8066536)
32. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash GB, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1431.
33. Owens DK, Harris A, Scott P: Screening Surgeons for HIV Infection. Ann Intern Med 1995; 122: 641-652.
34. Hillner BE, Smith TE: Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991; 324: 160-168.
35. Joyce T, Corman H, Grossman M: A cost-effectiveness analysis of strategies to reduce infant mortality. Med Care 1988; 26: 348-360.